REFERENCES
1. Gertzen CGW, Gohlke H, Häussinger D, et al. The many facets of bile acids in the physiology and pathophysiology of the human liver. Biol Chem 2021;402:1047-62.
2. Guo C, Qi H, Yu Y, et al. The G-protein-coupled bile acid receptor gpbar1 (tgr5) inhibits gastric inflammation through antagonizing NF-κB signaling pathway. Front Pharmacol 2015;6:287.
3. Pols TW, Noriega LG, Nomura M, Auwerx J, Schoonjans K. The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J Hepatol 2011;54:126-372.
4. Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009;10:167-77.
5. Jadhav K, Xu Y, Xu Y, et al. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR. Mol Metab 2018;9:131-40.
6. Wang XX, Wang D, Luo Y, et al. FXR/TGR5 dual agonist prevents progression of nephropathy in diabetes and obesity. J Am Soc Nephrol 2018;29:118-37.
7. Brønden A, Knop FK. Gluco-metabolic effects of pharmacotherapy-induced modulation of bile acid physiology. J Clin Endocrinol Metab 2020;105:362-73.
8. Velazquez-Villegas LA, Perino A, Lemos V, et al. TGR5 signalling promotes mitochondrial fission and beige remodelling of white adipose tissue. Nat Commun 2018;9:245.
9. Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006;439:484-9.
10. Schmid A, Schlegel J, Thomalla M, Karrasch T, Schäffler A. Evidence of functional bile acid signaling pathways in adipocytes. Mol Cell Endocrinol 2019;483:1-10.
11. Cimini FA, Barchetta I, Ciccarelli G, et al. Adipose tissue remodelling in obese subjects is a determinant of presence and severity of fatty liver disease. Diabetes Metab Res Rev 2021;37:e3358.
12. Barchetta I, Angelico F, Del Ben M, et al. Phenotypical heterogeneity linked to adipose tissue dysfunction in patients with Type 2 diabetes. Clin Sci (Lond) 2016;130:1753-62.
13. Barchetta I, Cimini FA, Capoccia D, et al. WISP1 is a marker of systemic and adipose tissue inflammation in dysmetabolic subjects with or without type 2 diabetes. J Endocr Soc 2017;1:660-70.
14. Barchetta I, Chiappetta C, Ceccarelli V, et al. Angiopoietin-like protein 4 overexpression in visceral adipose tissue from obese subjects with impaired glucose metabolism and relationship with lipoprotein lipase. Int J Mol Sci 2020;21:7197.
15. Svensson PA, Olsson M, Andersson-Assarsson JC, et al. The TGR5 gene is expressed in human subcutaneous adipose tissue and is associated with obesity, weight loss and resting metabolic rate. Biochem Biophys Res Commun 2013;433:563-6.
16. Bhandari M, Fobi MAL, Buchwald JN. Bariatric Metabolic Surgery Standardization (BMSS) Working Group. Standardization of bariatric metabolic procedures: world consensus meeting statement. Obes Surg 2019;29:309-45.
17. Diabetes Association. 1. Improving care and promoting health in populations: standards of medical care in diabetes-2020. Diabetes Care 2020;43:S7-S13.
18. Grundy SM, Cleeman JI, Daniels SR, et al. American Heart Association, National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
19. Meissburger B, Stachorski L, Röder E, Rudofsky G, Wolfrum C. Tissue inhibitor of matrix metalloproteinase 1 (TIMP1) controls adipogenesis in obesity in mice and in humans. Diabetologia 2011;54:1468-79.
20. Szántó M, Bai P. The role of ADP-ribose metabolism in metabolic regulation, adipose tissue differentiation, and metabolism. Genes Dev 2020;34:321-40.
21. Tinahones FJ, Coín Aragüez L, Murri M, et al. Caspase induction and BCL2 inhibition in human adipose tissue: a potential relationship with insulin signaling alteration. Diabetes Care 2013;36:513-21.
22. McQueen AE, Kanamaluru D, Yan K, et al. The C-terminal fibrinogen-like domain of angiopoietin-like 4 stimulates adipose tissue lipolysis and promotes energy expenditure. J Biol Chem 2017;292:16122-34.
23. van Zutphen T, Stroeve JHM, Yang J, et al. FXR overexpression alters adipose tissue architecture in mice and limits its storage capacity leading to metabolic derangements. J Lipid Res 2019;60:1547-61.
24. Barchetta I, Cimini FA, Capoccia D, et al. Neurotensin is a lipid-induced gastrointestinal peptide associated with visceral adipose tissue inflammation in obesity. Nutrients 2018;10:526.
25. McQueen AE, Koliwad SK, Wang JC. Fighting obesity by targeting factors regulating beige adipocytes. Curr Opin Clin Nutr Metab Care 2018;21:437-43.
26. Aryal B, Singh AK, Zhang X, et al. Absence of ANGPTL4 in adipose tissue improves glucose tolerance and attenuates atherogenesis. JCI Insight 2018;3:97918.
27. Wensveen FM, Valentić S, Šestan M, Turk Wensveen T, Polić B. The "Big Bang" in obese fat: events initiating obesity-induced adipose tissue inflammation. Eur J Immunol 2015;45:2446-56.
28. Verboven K, Wouters K, Gaens K, et al. Abdominal subcutaneous and visceral adipocyte size, lipolysis and inflammation relate to insulin resistance in male obese humans. Sci Rep 2018;8:4677.
29. Barchetta I, Cimini FA, Ciccarelli G, Baroni MG, Cavallo MG. Sick fat: the good and the bad of old and new circulating markers of adipose tissue inflammation. J Endocrinol Invest 2019;42:1257-72.
